Innocan Pharma's Liposomal CBD Platform Shows 28-Day Sustained Release in Preclinical Study
核心洞察
Innocan Pharma's LPT-CBD demonstrated sustained plasma CBD levels for 28 days following a single subcutaneous injection in Göttingen minipigs, a recognized translational model for human drug development.
The study revealed CBD metabolism patterns in minipigs that closely resemble human metabolism, with high levels of the 7-COOH-CBD (搜索) metabolite and no observed adverse effects throughout the study period.
The company has achieved FDA alignment on its non-clinical development plan, positioning the liposomal CBD platform for potential advancement toward human trials for non-opioid pain (搜索) management.
Innocan Pharma Corporation (搜索) has published promising preclinical results for its liposomal cannabidiol (LPT-CBD) drug delivery platform, demonstrating sustained release capabilities and favorable safety profiles in animal models. The study, published in Precision Nanomedicine, represents a significant milestone for the company's non-opioid pain (搜索) management program.
Extended Release Profile Achieved
The research evaluated LPT-CBD in three rabbits and three Göttingen minipigs administered single subcutaneous injections at ascending doses. The study monitored pharmacokinetics and safety parameters for 10 days in rabbits and 28 days in minipigs, revealing sustained CBD plasma concentrations throughout the entire 28-day observation period in the minipig model.
"This study, along with similar studies conducted in other animal models, confirms the sustained release of CBD following a single subcutaneous injection of LPT-CBD," stated Professor Chezy Barenholz, Head of the Advisory Board. The extended release profile addresses a key challenge in cannabinoid therapeutics, where conventional formulations typically require frequent dosing.
Human-Relevant Metabolism Patterns
The study demonstrated that minipigs exhibited CBD metabolism comparable to humans, with high blood levels of the 7-COOH-CBD (搜索) metabolite. This finding is particularly significant as Göttingen minipigs are widely recognized by regulatory authorities as a relevant non-rodent model for drug safety assessment due to their anatomical, physiological, and biochemical similarities to humans.
The metabolic profile observed in the study suggests the potential for predictable human pharmacokinetics, a critical factor in translating preclinical findings to clinical applications.
Safety Profile and Regulatory Alignment
No adverse effects were observed in minipigs throughout the study period, indicating good drug tolerability. Additionally, no local reactions were detected at injection sites, with only minimal histopathological findings reported. This safety profile supports the platform's potential for clinical development.
Dr. Eyal Kalo, Vice President of Research and Development, noted that "Innocan has reached alignment with the FDA on its non-clinical development plan." He added that "this preliminary study forms a strong foundation for further investigation into the pharmacokinetics and safety of LPT-CBD under regulatory compliance."
Liposomal Drug Delivery Platform
Innocan's LPT-CBD platform utilizes liposomal encapsulation technology to achieve exact dosing and controlled release of synthetic CBD. The company has positioned this technology for non-opioid pain (搜索) management applications, addressing the growing need for alternative pain therapies amid ongoing concerns about opioid-based treatments.
The liposomal delivery system represents an advancement in cannabinoid therapeutics, potentially offering improved bioavailability and duration of action compared to conventional CBD formulations. The sustained release profile demonstrated in this study could translate to reduced dosing frequency and improved patient compliance in clinical settings.